Boehringer Ingelheim Polska is the new partner of the Warsaw Health Innovation Hub
On January 23, the President of the Medical Research Agency, Mr. Radosław Sierpiński, MD, PhD and the CEO of Boehringer Ingelheim Polska, Mr. Michal Čuha, signed an agreement on the accession of Boehringer Ingelheim to the Warsaw Health Innovation Hub.
- I congratulate Boehringer Ingelheim on its 30th anniversary on the Polish market this year. Our meeting today only confirms that as a new partner of the Warsaw Health Innovation Hub, the company has extensive experience and understanding of the most important needs of the Polish healthcare system. Therefore, I am very positive about the initial proposals presented by Boehringer Ingelheim in such areas as telecardiology, lung disease or educational campaigns - touching on important issues from the point of view of a large part of society. I hope that soon we will be able to talk about the first fruits of good cooperation within WHIH - said the President of MRA.
- It is an honor for us to start cooperation with the Warsaw Health Innovation Hub - stressed Mr. Michal Čuha. - Our company has been operating on the Polish market for 30 years and throughout this period, developing innovative therapies that improve the quality of life of patients and often prolong their lives has been and still are our mission. We focus on areas where there are important unmet medical needs, such as diabetes, cardiology, pulmonology. We are involved in health education and a large part of our activities are directed directly to patients so that they become conscious participants in the therapeutic process. At the same time, we want to strengthen the health competences of the entire society. We believe that joining forces with the Warsaw Health Innovation Hub will result in many interesting projects and, above all, will contribute to developing solutions with the stakeholders of the health care system to improve the patient care scheme in Poland - noted the General Director of Boehringer Ingelheim Polska.
On behalf of Boehringer Ingelheim Polska, the meeting was also attended by Mr. Sebastian Schubert, Health Policy Director, Mrs. Anna Lech and Mr. Marcin Rynkowski.
The Boehringer Ingelheim Group is one of the 20 leading pharmaceutical companies in the world. It conducts research and development, production and sale of innovative medicinal products of high therapeutic value, intended for use in human and veterinary medicine.